Presentation is loading. Please wait.

Presentation is loading. Please wait.

MIGSYS Ian Evans, Genetics Max Musicant, SOM Grant Patterson, EPH Jia Kang, Med Informatics Colin Shaw, Nursing YBPS Case Competition November 20, 2009.

Similar presentations


Presentation on theme: "MIGSYS Ian Evans, Genetics Max Musicant, SOM Grant Patterson, EPH Jia Kang, Med Informatics Colin Shaw, Nursing YBPS Case Competition November 20, 2009."— Presentation transcript:

1 MIGSYS Ian Evans, Genetics Max Musicant, SOM Grant Patterson, EPH Jia Kang, Med Informatics Colin Shaw, Nursing YBPS Case Competition November 20, 2009

2 Patient Population Market Landscape Steroids Immunomodulators 5-ASAs Biologics 5-ASAs Steroids Immunomodulators Biologics

3 Target Market Drug Usage By Disease Severity MildModerateSevere Disease Severity MildModerateSevere Disease Severity GTX-001 Biologic GTX-002 Immunomodulator CD78,000 (20%) UC76,000 (14%) CD117,000 (37%) UC108,000 (37%) CD50,000 (37%) UC70,000 (48%) CD87,000 (27%) UC52,000 (18%) CD58,000 (43%) UC47,000 (32%)

4 Opportunity 1: Science Behind GTX-002 Identification Computational Design In Vitro Kinase Assays in two T- Cell Lines In Vivo Oral toxicity at 50mg/kg Altered GI flora Combo Therapy most effective

5 Finances GTX-002

6 Opportunity 2: Science Behind GTX-001 Mechanism of Action: mAb against  1  1 integrin Identification High Throughput Screening Target expression is more T H 1 specific (question of use in UC patients) In Vitro Abolished Interaction with Collagen In Vivo IV toxicity at 6mg/kg Effective at 2mg/kg every other day Reduced inflammation at 4-6 weeks

7 Released in 2004 for MS, Tysabri was then removed from market in 2005 due to cases of PML Reintroduced in 2005 and since restricted to smaller patient segment – To date 24 cases of PML found in Tysabri users GTX-001 is in the same class as Tysabri – mAb against  4-integrin – Decreases extravasation PML (Progressive Mulitfocal Leukoencephalopathy): a rare neurological disease Due Diligence

8 Finances GTX-001

9 Recommendation: GTX-002 Pros – A new class of kinase inhibitor Cons – Existing market well served by many products – Low market prices for immunomodulators – Signs of side effects in pre-clinical studies – Financial models show inviability Recommendation: NO GO

10 Recommendation: GTX-001 Pros – Large moderate and severe segments are underserved – Biologics command high prices in market – Large therapeutic window – Financial model shows significant profitability Cons – Similar mechanism to existing treatment (Tysabri) Significant medical risk associated with this class of molecules Recommendation: NO GO

11 Thank You from MIGSYS Ian Evans, Genetics Max Musicant, SOM Grant Patterson, EPH Jia Kang, Med Informatics Colin Shaw, Nursing

12 Tysabri, A Risky Proposition PML in patients who have received at least 24 infusions ranges from 0.4 to 1.3 per 1,000 in MS patients CD patients make up only 2% of the Tysabri users EMEA rejected Tysabri twice in 2007 Approved for the indication of CD in 2008 Strong warnings not to use Tysabri with PML in family history Case Report: N Engl J Med 2005;353: Previous FDA Alert: [issued 2/2006] The FDA has lifted the clinical hold on Biogen-IDEC's trials of natalizumab for patients with multiple sclerosis (MS). Biogen-IDEC can now resume administration of natalizumab to patients with relapsing-remitting MS who had previously been treated with the drug in clinical trials. Biogen-IDEC had previously suspended marketing of natalizumab and all further dosing of patients in on-going clinical trials. This decision was made after confirmation of one fatal case and one additional case of severely disabling progressive multifocal leukoencephalopathy (PML) in patients receiving natalizumab for MS. A third case of PML, this one fatal, in a patient with Crohn's Disease had been identified shortly thereafter.

13 Pro Forma GTX-001

14 Best and Worst Case GTX-001

15 GTX-002 Pro Forma

16 Best Case GTX-002


Download ppt "MIGSYS Ian Evans, Genetics Max Musicant, SOM Grant Patterson, EPH Jia Kang, Med Informatics Colin Shaw, Nursing YBPS Case Competition November 20, 2009."

Similar presentations


Ads by Google